Introduction

Jablońska’s linear IgA dermatosis and Duhring’s dermatitis herpetiformis were not distinguished until 1976. Before that time, there was confusion concerning the diagnostic criteria, nomenclature, and classification of this entity (1). Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear deposition of IgA along the skin basement membrane. LABD is usually idiopathic but may be associated with drugs, lymphoproliferative disorders, carcinoma, and systemic disease (2, 3). LABD has been reported to be induced by various drugs (4, 5). Histopathologically, LABD is characterized by the formation of subepidermal bullae with a predominantly neutrophilic infiltrate in the skin of the lesion. In LABD, the characteristic immunopathological finding is the presence of basement membrane zone (BMZ)–specific IgA class antibodies in a linear distribution on direct immunofluorescence (DIF) of perilesional skin in the absence of other immunoglobulin (6). However, these findings can also be seen in other subepidermal bullous diseases such as bullous pemphigoid (BP) and dermatitis herpetiformis (DH) (4, 7–9).

Clinical differences in typical cases of DH and BP are evident. In DH, characteristic polymorphous papulovesicular lesions, chiefly localized on the buttocks, elbows, knees, back, and head, are present. In BP, large, tense, sometimes hemorrhagic bullae can be present in any location. DH is usually related to celiac disease, whereas LABD and BP are usually related to tumor pathologies. Pruritus, if present in BP, is less severe than in DH, in which a burning sensation is also a characteristic feature. Dermatitis herpetiformis and bullous pemphigoid also differ considerably in histological features. In DH, polymorphonuclear microabscesses in dermal papillae around the bullae are highly characteristic. In BP there are subepidermal bullae either with or without inflammatory infiltrates, and a perivascular infiltrate, which also includes eosinophils (1, 10).

The distinction between BP and DH is further strengthened by differences in immunofluorescence findings. In DH, the characteristic immunopathological findings are deposits of granular IgA in the dermal papillae surrounding skin lesions without circulating antibodies. In the vast majority of cases of BP, IgG and complement are bound in vivo at the dermal-epidermal junction (1).

Diagnosis of LABD is difficult due to the similarity of its clinical symptoms with other bullous diseases. Therefore, further diagnostic examination tools such as DIF are needed to confirm the diagnosis. Here we report a case of LABD in a 41-year-old woman that we suspect was induced by acute myeloid leukemia.

Case report

A 41-year-old woman with acute myeloid leukemia presented to the dermatology and venereology department with multiple blisters and crusting on her back and abdomen that had appeared 1 month prior. In addition, multiple red papules had started to appear on her extremities. The symptoms were accompanied by itching and burning sensations. The patient admitted taking antibiotics and analgesics in the previous 2 weeks. A history of similar complaints was denied.

Physical examination showed vital signs within normal limits. Dermatological examination on the posterior truncal region revealed clusters of tense erythematous vesicles and bullae resembling a “cluster of jewels” along with crusting and erosion (Fig. 1A–B). No abnormalities were found on the mucous membrane of the eyes, mouth, or genitals. Based on history and physical examination, the patient was differentially diagnosed with LABD, dermatitis herpetiformis, and bullous pemphigoid.

Histopathological examination with hematoxylin and eosin (H&E) staining revealed inflammation on the superficial dermis with perivascular and interstitial lymphocyte infiltration mixed with neutrophils; the dermis area appeared edematous. These features, although not pathognomonic, may support the diagnosis of LABD (Fig. 2A–C). Subsequent DIF examination found weak and focal IgA deposits at the dermal-epidermal junction. No IgG, IgM, or C deposits were found. These results confirmed the diagnosis of LABD (Fig. 3).

The patient was then treated with 16 mg oral methylprednisolone b.i.d., 10 mg oral cetirizine daily, and a topical combination of 0.1% betamethasone cream and 2% fusidic acid cream applied
twice daily. Three days after treatment, complaints of itching improved. In addition, the cutaneous lesions started to resolve. At a 1-month follow-up, the patient felt no pain or pruritus. Improvements were also seen on the lesions, with resolution of the bullae and vesicles leaving only hyperpigmented macules and slight crusting (Fig. 4).

Discussion

LABD is a rare subepidermal bullous disease with an incidence of approximately 0.5 cases per million in southwestern Europe. The disease has a higher occurrence in children and the elderly (> 60 years). The disease has no gender or racial predominance (4, 11). The clinical presentation of LABD is usually heterogeneous, mostly involving the skin, although oral manifestations have occasionally been reported (11, 12). Although very rare, mucosal lesions can act as the single clinical presentation and may precede cutaneous lesions (12, 13). Because there are various differential diagnoses for bullous diseases, a thorough history-taking and physical examination combined with confirmation by histopathology and DIF were necessary to exclude potential differential diagnoses such as BP and epidermolysis bullosa acquisita.

In our patient, dermatological examination revealed multiple
vesicles on the abdomen alongside numerous vesicles and bullae that coalesced on the posterior truncal region resembling a “cluster of jewels” along with crusting. These findings were accompanied by pruritus and a burning sensation. The “cluster of jewels” appearance is a typical characteristic of LABD (7, 11, 14, 15).

The exact pathogenesis of LABD is yet to be established. It is thought to be drug-related or a systemic autoimmune disease. The association between LABD and drug exposure, most commonly vancomycin, has been widely reported (4, 5, 12, 16). However, we suspect that the cause of LABD in our patient was due to acute myeloid leukemia. This is consistent with literature that reports a correlation between malignancies and LABD (7, 11, 17). LABD can also be induced by tumor pathologies, in particular of the blood. There are reports of LABD associations with Hodgkin’s lymphoma (18), angioimmunoblastic T-cell lymphoma (19), acute lymphoblastic leukemia (20) and its chronic form (chronic lymphocytic leukemia) (21), and chronic myeloid leukemia (22). Therefore, it is emphasized that a case of LABD associated with acute myeloid leukemia has previously been described. However, whether LABD is a paraneoplastic manifestation of lymphoproliferative disease triggered by abnormal immune processes, has yet to be investigated (23).

Histopathological examination of our patient showed inflammation in the superficial dermis in the form of perivascular and interstitial lymphocyte infiltration mixed with neutrophils, with edema in the dermis. This is in accordance with the literature, which reports that the histopathological picture in LABD is the presence of subepidermal bullae with dominant infiltrates of neutrophils and eosinophils, and mononuclear cells (4, 24, 25). To confirm the diagnosis, DIF was performed, showing weak and focal IgA deposits at the dermal-epidermal junction, which confirmed the diagnosis of LABD (4, 11, 12). The gold standard for the diagnosis of LABD is the presence of BMZ-specific IgA class antibodies in a linear distribution on DIF of perilesional skin in the absence of other immunoglobulins. The antibodies are usually IgA1 subclass, but IgA2 BMZ-specific antibodies have also been described in a minority of cases. The majority of these antibodies bind to the epidermal side of BMZ-split human skin, with a minority of these antibodies binding to the dermal side. Occasionally, antibody binding to both sides of the split can be observed (6). This is why sometimes one can only find weak and focal IgA deposits at the dermal-epidermal junction.

Dapsone is considered the first-line therapy for LABD. Its efficacy has been proven as monotherapy or in combination with other drugs, such as corticosteroids, nicotinamide, and antibiotics. In addition, new and safe alternative therapies, such as intravenous immunoglobulin and immunoadsorption, have been used successfully over the past 10 years (4, 12, 25). However, because dapsone was not available at our center, in this case the patient was treated using oral corticosteroids with the recommended dosage equivalent to 0.5 to 2 mg/kgBW prednisone daily (12). The patient weighed 50 kg, and so a dosage of 36 mg daily seemed to be suitable treatment for the patient, and this was followed by significant clinical improvement (12, 27). Topical corticosteroids were also applied in our patient along with topical antibiotics to prevent infections. A study by Saenz et al. reported that, when treatment with dapsone is not available, topical corticosteroids can be an alternative, either alone or in conjunction with other treatments (28). After 1 month of treatment, the lesions mostly resolved, leaving only hyperpigmented macules and plaques along with slight crusting.

Conclusions

LABD is a rare bullous disease that can mimic other dermatoses. Clinical manifestation of a “cluster of jewels” appearance along with histopathological and DIF features can aid in diagnostic confirmation. In our case, a combination of oral and topical corticosteroids provided excellent results.
References


